Opportunities in the SMA market include leveraging the launch of new myostatin inhibitors, expanding Zolgensma formulations to increase patient eligibility, and capitalizing on cheap nusinersen ...
On 25 November 2025, Novartis Pharmaceuticals conducted a study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with ...
Dublin, July 29, 2024 (GLOBE NEWSWIRE) -- The "Spinal Muscular Atrophy: Opportunity Assessment and Forecast 2023-2033" report has been added to ResearchAndMarkets.com's offering. The diagnosed ...
DelveInsight’s, “Spinal Muscular Atrophy Pipeline Insight 2024” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Spinal muscular atrophy pipeline landscape. It ...
Emmes today announced that Casimir’s research on the development of the Duchenne Video Assessment (DVA) scorecards was published in PLOS ONE. Emmes acquired Casimir in March 2022, and the group is now ...
The drug vamorolone (Agamree ®) has been hailed as a promising new drug to treat Duchenne muscular dystrophy (DMD). It has recently been approved for clinical use in the United States by the Food and ...
Understanding individual muscle strength is crucial for optimizing physical therapy and enhancing athletic performance. Traditional methods, however, often fall short in precision. The newly ...
The Open Orthopaedics Journal recently published "Inter-rater Reliability of Sustained Aberrant Movement Patterns as a Clinical Assessment of Muscular Fatigue" by: Frank Aerts, PT, DSc, OCS, CMPT, CMP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback